

SUPPLEMENTAL MATERIAL

Table S1. Comparison of baseline characteristics between patients with and without available quality of life data.

	Total (n = 339)	SF36 available (n=196)	SF36 not available (n=143)	P-value
Demographics				
Age (years)	44.3 (+/- 13.9)	44.3 (+/- 13.8) *	44.3 (+/- 14.0)	0.992
Male (%)	179 (53)	100 (51)	79 (55)	0.442
Medical history				
Congenital Heart Disease				0.986
<i>Simple</i>	30 (9)	17 (9)	13 (9)	
<i>Moderate</i>	119 (35)	69 (35)	50 (35)	
<i>Complex</i>	187 (56)	109 (56)	78 (55)	
Previous cardiac surgery	282 (83)	167 (85)	115 (80)	0.245
Renal failure	23 (7)	9 (5)	14 (10)	0.052
COPD	16 (5)	8 (4)	8 (6)	0.514
PAH	68 (20)	35 (18)	33 (23)	0.236
Diabetes	15 (4)	9 (5)	6 (4)	0.872
History of heart failure hospitalization	115 (56)	61 (54)	54 (58)	0.605
Depression	25 (8)	17 (9)	8 (6)	0.290
Clinical characteristics				
BMI (kg/m ²)	24.8 (+/- 5.8)	25.4 (+/-6.0)	25.0 (+/-5.6)	0.748
NYHA			p for III/IV vs others :	0.821
<i>I</i>	33 (10)	23 (12)	10 (8)	
<i>II</i>	135 (42)	77 (41)	58 (44)	
<i>III</i>	122 (38)	70 (37)	52 (40)	
<i>IV</i>	29 (9)	18 (10)	11 (8)	
Systolic blood pressure (mmHg)	117 (+/-16)	117 (+/-17)	117 (+/- 15)	0.669

Diastolic blood pressure (mmHg)	68 (+/- 12)	67 (+/- 12)	70 (+/- 11)	0.048
Heart beat (b.p.m)	77 (+/- 19)	77 (+/- 19)	77 (+/- 20)	0.790
Sodium (mmol/L)	139 (+/- 3)	139 (+/- 3)	138 (+/- 4)	0.111
BNP (ng/L)	245 [133 - 615] **	220 [129 - 507]	297 [147 - 806]	0.156
GFR (MDRD)	88 (+/- 31)	90 (+/- 32)	85 (+/- 30)	0.184
Haemoglobin	14.1 (+/- 2.7)	14.0 (+/- 2.7)	14.2 (+/- 2.8)	0.575
VEF (%)	46.9 (+/- 12.3)	46.6 (+/- 11.6)	47.3 (+/- 13.5)	0.683
Medication at the time of the inclusion				
Loop diuretics	192 (59)	113 (59)	79 (59)	0.985
ACE inhibitors	113 (35)	82 (43)	31 (23)	< 0.001
Beta-blockers	180 (55)	120 (63)	60 (45)	0.002

* Mean (+/- standard deviation); ** Median [interquartile range]; *** Death or transplantation or HF hospitalisation or circulatory support. ACE, angiotensin conversion enzyme; BMI, body mass index; BNP, brain natriuretic peptide; COPD, Chronic obstructive pulmonary disease; EF, ejection fraction; GFR, glomerular filtration rate; PAH, pulmonary arterial.

Figure S1. The survival curve with censored data.

